journal article
LitStream Collection
Home
Daffner, Kirk R.; O’Connor, Margaret
doi: 10.1001/jamaneurol.2024.2461pmid: 39133469
This Viewpoint advocates for Medicare coverage of driving assessments for older individuals.
Condello, Carlo; Westaway, David; Prusiner, Stanley B.
doi: 10.1001/jamaneurol.2024.2464pmid: 39158847
This Viewpoint describes the evidence for iatrogenic disease based on amyloid-β prions and the possibility that Alzheimer disease has an iatrogenic form wherein amyloid β and tau behave as prions that transmit the disease.
doi: 10.1001/jamaneurol.2024.2835pmid: 39226025
This essay describes the author’s observations while examining a pregnant mother who has multiple sclerosis.
Belloy, Michael E.; Le Guen, Yann; Stewart, Ilaria; Williams, Kennedy; Herz, Joachim; Sherva, Richard; Zhang, Rui; Merritt, Victoria; Panizzon, Matthew S.; Hauger, Richard L.; Gaziano, J. Michael; Logue, Mark; Napolioni, Valerio; Greicius, Michael D.
doi: 10.1001/jamaneurol.2024.2843pmid: 39250132
Wisse, Laura E. M.; Spotorno, Nicola; Rossi, Marcello; Grothe, Michel J.; Mammana, Angela; Tideman, Pontus; Baiardi, Simone; Strandberg, Olof; Ticca, Alice; van Westen, Danielle; Mattsson-Carlgren, Niklas; Palmqvist, Sebastian; Stomrud, Erik; Parchi, Piero; Hansson, Oskar
Showing 1 to 10 of 21 Articles
Key PointsQuestionDoes the X chromosome play a role in the genetics of Alzheimer disease (AD)? FindingsIn a genetic meta-analysis across 1 152 284 individuals, several X chromosome loci were associated with AD. Four loci showed evidence of shared genetic associations between AD risk and regulation of nearby gene expression in brain tissue; the top association signal was intronic on SLC9A7 and linked to its expression. MeaningThe results of this large-scale X chromosome–wide association study of AD prioritized SLC9A7 as a novel risk locus, advancing our knowledge of AD genetics and providing novel biological drug targets.
doi: 10.1001/jamaneurol.2024.2652pmid: 39186280
Key PointsQuestionWhat are the long-term clinical outcomes of endovascular thrombectomy compared with best medical treatment for patients with acute basilar artery occlusion within 12 hours of estimated symptom onset? FindingsIn this secondary analysis of a randomized clinical trial, favorable outcome rates in the thrombectomy and the control groups were similar at 1 year as at 90 days. Mortality outcomes increased between day 90 and 1 year in both groups, while excellent outcomes increased between day 90 and 1 year in the thrombectomy group but not in the control group. MeaningThe findings suggest that the benefits of endovascular thrombectomy in patients with acute basilar artery occlusion were sustained at long-term follow-up.
doi: 10.1001/jamaneurol.2024.2713pmid: 39068668
This cohort study investigates the association between cerebrospinal fluid seed amplification α-synuclein positivity and magnetic resonance imaging (MRI) structural measures across the continuum from clinically unimpaired to cognitively impaired individuals.